Follicular lymphoma: Update on management and emerging therapies at the dawn of the new decade

Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma

(2020) Patrizia Mondello et al.   BLOOD

Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma

(2020) Franck Morschhauser et al.   BLOOD

Combined EZH2 and BCL2 Inhibitors As Precision Therapy for Genetically Defined DLBCL Subtypes

(2020) Destini Gibbs et al.   BLOOD

Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma Treated within the Gallium Trial: EZH2 mutation Status May be a Predictive Marker for Differential Efficacy of Chemotherapy

(2020) Vindi Jurinovic et al.   BLOOD

Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)

(2019) Franck Morschhauser et al.   Lancet Haematology

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma

(2019) John P. Leonard et al.   JOURNAL OF CLINICAL ONCOLOGY

First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study

(2019) Ian W. Flinn et al.   JOURNAL OF CLINICAL ONCOLOGY

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma

(2019) Ian W. Flinn et al.   JOURNAL OF CLINICAL ONCOLOGY

Is Longer Progression-Free Survival a Goal Worth Pursuing in Follicular Lymphoma?

(2019) Marc Sorigue et al.   JOURNAL OF CLINICAL ONCOLOGY

The future of cell-free DNA testing to guide therapeutic decisions in B-cell lymphomas

(2019) Adalgisa Condoluci et al.   CURRENT OPINION IN HEMATOLOGY

High Rate of Durable Complete Remission in Follicular Lymphoma after CD19 CAR-T cell Immunotherapy

(2019) Alexandre V. Hirayama et al.   BLOOD

Early progression after BR is associated with high risk of transformation in advanced stage follicular lymphoma

(2019) Ciara L. Freeman et al.   BLOOD

RESPONSE ORIENTED MAINTENANCE THERAPY IN ADVANCED FOLLICULAR LYMPHOMA. RESULTS OF THE INTERIM ANALYSIS OF THE FOLL12 TRIAL CONDUCTED BY THE FONDAZIONE ITALIANA LINFOMI.

(2019) M. Federico et al.   HEMATOLOGICAL ONCOLOGY

PREDICTIVE VALUE OF POD24 VALIDATION IN FOLLICULAR LYMPHOMA PATIENTS INITIALLY TREATED WITH CHEMOTHERAPY-FREE REGIMENS IN A POOLED ANALYSIS OF THREE RANDOMIZED TRIALS OF THE SWISS GROUP FOR CLINICAL CANCER RESEARCH (SAKK).

(2019) A. Moccia et al.   HEMATOLOGICAL ONCOLOGY

EFFICACY AND SAFETY OF OBINUTUZUMAB + LENALIDOMIDE + ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 1B/2 TRIAL

(2019) F. Morschhauser et al.   HEMATOLOGICAL ONCOLOGY

THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY HU5F9-G4 + RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS

(2019) R. Advani et al.   HEMATOLOGICAL ONCOLOGY

NCRI PETREA TRIAL: A PHASE 3 EVALUATION OF PET-GUIDED, RESPONSE-ADAPTED THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED, ADVANCED-STAGE, HIGH-TUMOUR-BURDEN FOLLICULAR LYMPHOMA

(2019) A.R. Pettitt et al.   HEMATOLOGICAL ONCOLOGY

PROGNOSTIC VALUE OF PRE-TREATMENT PET SCAN IN PATIENTS WITH FOLLICULAR LYMPHOMA RECEIVING FRONTLINE THERAPY

(2019) P. Strati et al.   HEMATOLOGICAL ONCOLOGY

CD20-TCB (RG6026), A NOVEL “2:1” FORMAT T-CELL-ENGAGING BISPECIFIC ANTIBODY, INDUCES COMPLETE REMISSIONS IN RELAPSED/REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA

(2019) M.J. Dickinson et al.   HEMATOLOGICAL ONCOLOGY

SAKK 35/15: A PHASE I TRIAL OF OBINUTUZUMAB IN COMBINATION WITH VENETOCLAX IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA PATIENTS

(2019) A. Stathis et al.   HEMATOLOGICAL ONCOLOGY

AUGMENT PHASE III STUDY: LENALIDOMIDE/RITUXIMAB (R2 ) IMPROVED EFFICACY OVER RITUXIMAB/PLACEBO IN RELAPSED/REFRACTORY FOLLICULAR PATIENTS IRRESPECTIVE OF POD24 STATUS

(2019) J. Leonard et al.   HEMATOLOGICAL ONCOLOGY

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study

(2019) Emmanuel Bachy et al.   JOURNAL OF CLINICAL ONCOLOGY

Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration

(2019) Joshua W.D. Tobin et al.   JOURNAL OF CLINICAL ONCOLOGY

Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis

(2018) Carla Casulo et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma: A Follow-Up Study of 2 Randomized Trials from the German Low Grade Lymphoma Study Group

(2018) Vindi Jurinovic et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study

(2018) Anne Ségolène Cottereau et al.   BLOOD

A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy

(2018) Emmanuel Bachy et al.   BLOOD

Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016

(2018) Mazyar Shadman et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma

(2018) Stefano Luminari et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study

(2018) Bruce D. Cheson et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Trial of Systemic Therapy After Involved-Field Radiotherapy in Patients With Early-Stage Follicular Lymphoma: TROG 99.03

(2018) Michael MacManus et al.   JOURNAL OF CLINICAL ONCOLOGY

A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts

(2018) Sarah Huet et al.   LANCET ONCOLOGY

Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis

(2018) Massimo Federico et al.   Lancet Haematology

Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue treatment

(2018) Ana Jiménez-Ubieto et al.   HEMATOLOGICAL ONCOLOGY

Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL.

(2018) Laurie Helen Sehn et al.   JOURNAL OF CLINICAL ONCOLOGY

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

(2018) Franck Morschhauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG

(2018) Jessica L. Brady et al.   BLOOD

Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era

(2018) Alfredo Rivas-Delgado et al.   BRITISH JOURNAL OF HAEMATOLOGY

Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression

(2018) John F. Seymour et al.   HAEMATOLOGICA

Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up

(2018) Sandra Lockmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts

(2018) Clémentine Sarkozy et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

(2018) Frederick L Locke et al.   LANCET ONCOLOGY

Macrophage Checkpoint Blockade in Cancer — Back to the Future

(2018) Alberto Mantovani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

(2018) Ranjana Advani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials

(2017) Qian Shi et al.   JOURNAL OF CLINICAL ONCOLOGY

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma

(2017) Martin Dreyling et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

(2017) Matthew S. Davids et al.   JOURNAL OF CLINICAL ONCOLOGY

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma

(2017) Robert Marcus et al.   NEW ENGLAND JOURNAL OF MEDICINE

EZH2 alterations in follicular lymphoma: biological and clinical correlations

(2017) S Huet et al.   Blood Cancer Journal

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

(2016) M. Dreyling et al.   ANNALS OF ONCOLOGY

Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy

(2016) V. Jurinovic et al.   BLOOD

The 2016 revision of the World Health Organization classification of lymphoid neoplasms

(2016) S. H. Swerdlow et al.   BLOOD

The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≤12 months

(2016) Matthew A. Lunning et al.   BRITISH JOURNAL OF HAEMATOLOGY

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

(2016) Alexander M. Lesokhin et al.   JOURNAL OF CLINICAL ONCOLOGY

Baseline Metabolic Tumor Volume Predicts Outcome in High–Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies

(2016) Michel Meignan et al.   JOURNAL OF CLINICAL ONCOLOGY

Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial

(2016) Clémentine Sarkozy et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway

(2016) Vassiliki A. Boussiotis   NEW ENGLAND JOURNAL OF MEDICINE

Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi

(2015) S. Luminari et al.   HAEMATOLOGICA

Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study

(2015) Carla Casulo et al.   JOURNAL OF CLINICAL ONCOLOGY

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry

(2015) Alessandro Pastore et al.   LANCET ONCOLOGY

Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi

(2015) S. Luminari et al.   HAEMATOLOGICA

Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma

(2014) Baldeep Wirk et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Rituximab Extended Schedule or Re-Treatment Trial for Low–Tumor Burden Follicular Lymphoma: Eastern Cooperative Oncology Group Protocol E4402

(2014) Brad S. Kahl et al.   JOURNAL OF CLINICAL ONCOLOGY

Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial

(2014) Kirit M Ardeshna et al.   LANCET ONCOLOGY

Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry Study

(2014) H R Junlén et al.   LEUKEMIA

PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

(2014) Ajay K. Gopal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies

(2014) Judith Trotman et al.   Lancet Haematology

Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience

(2013) D. Tan et al.   BLOOD

EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation

(2013) Wendy Béguelin et al.   CANCER CELL

R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Follicular Lymphoma: Results of the FOLL05 Trial Conducted by the Fondazione Italiana Linfomi

(2013) Massimo Federico et al.   JOURNAL OF CLINICAL ONCOLOGY

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

(2013) Mathias J Rummel et al.   LANCET

Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma

(2013) Jessica Okosun et al.   NATURE GENETICS

Effectiveness of First-Line Management Strategies for Stage I Follicular Lymphoma: Analysis of the National LymphoCare Study

(2012) Jonathan W. Friedberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus131Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: SWOG S0016

(2012) Oliver W. Press et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation

(2010) Thomas J. Pugh et al.   CANCER

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

(2010) Gilles Salles et al.   LANCET

Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up

(2009) M. Kornacker et al.   ANNALS OF ONCOLOGY

Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy

(2009) A. G. Ramsay et al.   BLOOD

Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project

(2009) Massimo Federico et al.   JOURNAL OF CLINICAL ONCOLOGY

Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma

(2008) C. Bodet-Milin et al.   HAEMATOLOGICA

Population-Based Analysis of Incidence and Outcome of Transformed Non-Hodgkin's Lymphoma

(2008) Abdulwahab J. Al-Tourah et al.   JOURNAL OF CLINICAL ONCOLOGY